Literature DB >> 1859053

Severe community-acquired pneumonia. Epidemiology and prognostic factors.

A Torres1, J Serra-Batlles, A Ferrer, P Jiménez, R Celis, E Cobo, R Rodriguez-Roisin.   

Abstract

Over a period of 4 consecutive yr, 92 nonimmunosuppressed patients (21 women and 71 men aged 53 +/- 16 yr, means = SD) with critical acute respiratory failure (PaO2/FiO2, 209 +/- 9 mm Hg) caused by severe community-acquired pneumonia were admitted to the respiratory intensive care unit (RICU) of a general hospital. The most frequent underlying clinical condition was chronic obstructive pulmonary disease (44 patients, 48%). A total of 56 patients (61%) required mechanical ventilation for a mean period of 10.7 +/- 12.5 days, 29 of them (52%) needing PEEP (9.9 +/- 3.8 cm H2O). A group of 23 (25%) patients had criteria of adult respiratory distress syndrome (ARDS). A causal microorganism was identified in 48 patients (52%), the two most frequent etiologies being Streptococcus pneumoniae (14, 15%) and Legionella pneumophila (13, 14%). Pseudomonas aeruginosa (5, 5%) was always associated with bronchiectasis. Mortality due to severe community-acquired pneumonia was 22% (20 patients). According to univariate analysis, mortality was associated with anticipated death within 4 to 5 yr, inadequate antibiotic treatment before RICU admission, mechanical ventilation requirements, use of PEEP, FIO2 greater than 0.6, coexistence of ARDS, radiographic spread of the pneumonia during RICU admission, septic shock, bacteremia, and P. aeruginosa as the cause of the pneumonia. Further, recursive partitioning analysis selected two factors significantly related to the prognosis: the radiographic spread of the pneumonia during RICU admission and the presence of septic shock.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1859053     DOI: 10.1164/ajrccm/144.2.312

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  104 in total

1.  Anaerobic Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 3.  The pulmonary physician in critical care 1: pulmonary investigations for acute respiratory failure.

Authors:  J Dakin; M Griffiths
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

Review 4.  The pulmonary physician in critical care . 3: critical care management of community acquired pneumonia.

Authors:  S V Baudouin
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

5.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

6.  Characteristics associated with clinician diagnosis of aspiration pneumonia: a descriptive study of afflicted patients and their outcomes.

Authors:  Michael J Lanspa; Paula Peyrani; Timothy Wiemken; Emily L Wilson; Julio A Ramirez; Nathan C Dean
Journal:  J Hosp Med       Date:  2014-11-01       Impact factor: 2.960

7.  Community-Acquired Pneumonia: An Overview.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

8.  Initial antimicrobial treatment of hospital acquired pneumonia in adults: A conference report.

Authors:  L A Mandell; T J Marrie; M S Niederman
Journal:  Can J Infect Dis       Date:  1993-11

9.  Antimicrobial treatment of community acquired pneumonia in adults: A conference report.

Authors:  L Mandell; M Niederman
Journal:  Can J Infect Dis       Date:  1993-01

10.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.